For people living with Huntington's disease — and for the families watching it take its relentless toll — June 17, 2026, may eventually be remembered as the day the trajectory of the disease changed.
uniQure N.V. announced that morning that during a recent Type B meeting with the FDA, the agency confirmed that three-year data from the Phase I/II study of AMT-130 — its gene therapy for Huntington's disease — would be acceptable as the primary basis for a Biologics License Application seeking accelerated approval. The company intends to submit the BLA in the third quarter of 2026.
The press release published via Globe Newswire sent uniQure's shares up approximately 70% on the day's trading — a market reaction that reflects the magnitude of what this regulatory alignment represents for a disease that has never had an approved disease-modifying treatment anywhere in the world.
What AMT-130 Is — and How It Works
AMT-130 is a one-time, investigational adeno-associated virus (AAV) vector-based gene therapy that is delivered directly into the brain through MRI-guided stereotactic neurosurgery. The therapy uses RNA interference (RNAi) to silence the mutant huntingtin gene (mHTT) — the genetic driver of Huntington's disease — reducing the production of the toxic mutant huntingtin protein that causes the progressive neurodegeneration characteristic of the disease.
Huntington's disease is caused by an expanded CAG repeat in the HTT gene, inherited in an autosomal dominant pattern — meaning one copy of the mutated gene is sufficient to cause the disease. Carriers know they will develop the condition. Its hallmarks include progressive movement dysfunction (chorea, dystonia), cognitive decline, and psychiatric symptoms, including depression and anxiety. It is uniformly fatal, typically within 10 to 20 years of symptom onset. Current standard of care is entirely symptomatic — managing chorea, managing psychiatric symptoms, supporting quality of life — with no agent proven to slow the underlying neurodegeneration.
According to NeurologyLive's comprehensive coverage of the June 17 announcement, the high-dose AMT-130 cohort met the primary endpoint at 3 years, showing 75% slowing of cUHDRS progression versus Enroll-HD propensity-matched external controls (P = .003). The cUHDRS — composite Unified Huntington's Disease Rating Scale — is a validated, multi-domain measure of disease progression that the FDA has agreed may serve as an intermediate clinical endpoint for accelerated approval in this case.
| AMT-130 BLA and Regulatory Key Data | Detail |
| Company | uniQure N.V. (NASDAQ: QURE) |
| Announcement date | June 17, 2026 (Globe Newswire, 7:05 AM ET) |
| FDA communication | Type B meeting confirming 3-year Phase I/II data acceptable for accelerated approval BLA |
| BLA submission timeline | Q3 2026 |
| Therapy type | AAV vector-based gene therapy (one-time intracranial delivery) |
| Mechanism | RNAi-mediated silencing of mutant huntingtin gene (mHTT) |
| Delivery route | MRI-guided stereotactic neurosurgery into the striatum |
| Primary efficacy finding (high dose, 3-year) | 75% cUHDRS progression slowing vs. Enroll-HD external controls (P = .003) |
| Regulatory designations | RMAT (first HD designation), Breakthrough Therapy, Fast Track |
| Endpoint accepted for accelerated approval | cUHDRS (composite Unified HD Rating Scale) as intermediate clinical endpoint |
| Confirmatory trial design | FDA and uniQure aligning on concurrent standard-of-care control (not sham) |
| Share price reaction | ~+70% on June 17, 2026 |
| Phase I/II trial registrations | NCT04120493 (U.S.); NCT05243017 (European) |
| Approved HD disease-modifying therapies worldwide | None (as of June 2026) |
The Path to This Point — A Complex Regulatory Journey
The announcement came after a difficult detour. In November 2025, uniQure disclosed that the FDA was no longer in alignment on the acceptability of external controls from the Enroll-HD natural history database as the primary comparator for a BLA. This was a significant reversal from a prior alignment in June 2025 — one that had allowed uniQure to plan an early 2026 BLA submission.
The November misalignment forced a strategic reassessment. The June 17, 2026 Type B meeting restored alignment — though with modifications. According to the uniQure pipeline page, the FDA now seeks alignment on a confirmatory study design that uses a concurrent control on standard-of-care therapy rather than a sham neurosurgical procedure — a meaningful shift that acknowledges both the ethical challenges of sham brain surgery controls and the scientific need for a rigorous post-market confirmatory study.
"We are very pleased to reach agreement with the FDA on core components of an accelerated approval pathway for AMT-130," said Walid Abi-Saab, M.D., Chief Medical Officer of uniQure. "Our alignment reflects the strength of our data and collaborative discussions with the staff and senior management at FDA's Center for Biologics Evaluation and Research. This is an important milestone for the Huntington's disease community as it puts us on the most rapid and efficient pathway to deliver a potentially life-changing therapy to people living with this devastating neurodegenerative disorder."
AMT-130's three regulatory designations — RMAT (the FDA's most accelerated development status), Breakthrough Therapy, and Fast Track — collectively give uniQure rolling review eligibility (the ability to submit BLA components for review as they are completed rather than waiting for a complete application) and intensive FDA collaboration rights. These designations exist for exactly this scenario: a single-administration gene therapy with early clinical evidence in a disease with no alternatives.
What Accelerated Approval Means — and What Comes Next
Accelerated approval is a regulatory pathway that allows the FDA to approve a drug or biologic based on an intermediate endpoint — one that is reasonably likely to predict clinical benefit — rather than waiting for direct evidence of long-term clinical outcomes. The 75% cUHDRS progression slowing at three years is the intermediate endpoint supporting the BLA; whether this translates to meaningful long-term functional preservation will be assessed in the required post-market confirmatory trial.
Accelerated approval does not mean permanent approval. If the confirmatory trial fails to verify clinical benefit, the FDA can withdraw accelerated approval. This is the regulatory mechanism that gives the agency flexibility to provide earlier access to potentially transformative therapies while maintaining scientific rigor through the post-market requirement.
For the approximately 30,000 Americans living with Huntington's disease — and the additional 200,000 estimated to be at 50% genetic risk — the prospect of an approved therapy that slows progression rather than merely managing symptoms represents a categorically different future than the disease has ever offered. Whether AMT-130 ultimately fulfills that promise will depend on the confirmatory trial. But the accelerated approval pathway, if the BLA is approved, would give access to the therapy years before that confirmation is complete.
The confirmed BLA submission in Q3 2026 means a filing as soon as October 2026. Standard FDA review timelines for a BLA, with rolling review, could produce a decision as early as mid-2027 — though timelines vary and are not guaranteed.
Frequently Asked Questions
What is AMT-130, and what did uniQure announce on June 17, 2026?
AMT-130 is a one-time gene therapy for Huntington's disease that uses RNA interference to silence the mutant huntingtin gene in the brain. On June 17, 2026, uniQure announced that the FDA agreed 3-year Phase I/II clinical data could serve as the primary basis for a BLA for accelerated approval. uniQure plans to submit the BLA in Q3 2026.
What evidence supports AMT-130's effectiveness?
In the high-dose cohort of the Phase I/II study at 3 years, AMT-130 showed 75% slowing of cUHDRS (composite Unified Huntington's Disease Rating Scale) progression compared to propensity-matched external controls from the Enroll-HD database (P = .003). The FDA agreed the cUHDRS may serve as an intermediate clinical endpoint for accelerated approval purposes.
What regulatory designations does AMT-130 have?
AMT-130 holds three FDA designations: RMAT (Regenerative Medicine Advanced Therapy — the FDA's most accelerated development status, and the first ever granted for Huntington's disease), Breakthrough Therapy designation, and Fast Track designation.
What is the confirmatory trial requirement?
Under accelerated approval, uniQure must conduct a post-market confirmatory trial demonstrating clinical benefit. The FDA and uniQure are aligning on a design using a concurrent standard-of-care control arm rather than a sham neurosurgical procedure.
Is there currently any approved treatment that slows Huntington's disease?
No. As of June 2026, there is no approved disease-modifying treatment for Huntington's disease anywhere in the world. Current management is entirely symptomatic.
